Literature DB >> 9592055

Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-alpha production.

R Cocchiara1, A Bongiovanni, G Albeggiani, A Azzolina, D Geraci.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) levels in mammalian brain increase during neuroinflammatory diseases. We used the competitive polymerase chain reaction (PCR) to quantify the amount of TNF-alpha in stimulated and unstimulated brain mast cells (BMC). A cDNA fragment shortened by a deletion of 56 bp was used as an internal TNF-alpha-specific standard. The immunological stimulus resulted in enhanced TNF-alpha mRNA expression and increased release of histamine and TNF-alpha. This is the first time that BMC showing functional FCepsilonRI-bound IgE receptors have been purified. Our results support the hypothesis that BMC mediators might induce an initial response in neuroinflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592055     DOI: 10.1097/00001756-199801050-00019

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  6 in total

Review 1.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Mast cells are necessary for the hypothermic response to LPS-induced sepsis.

Authors:  Katherine M Nautiyal; Heather McKellar; Ann-Judith Silverman; Rae Silver
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-24       Impact factor: 3.619

3.  Fetuin in human bone marrow: detection in foetal tissue and patients with mastocytosis.

Authors:  K M Dziegielewska; H P Horny; P Valent; M D Habgood; U Schumacher
Journal:  Histochem J       Date:  2001-08

4.  Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome.

Authors:  Magdalini Vasiadi; Jennifer Newman; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2014-10-31       Impact factor: 8.322

5.  Luteolin as a therapeutic option for multiple sclerosis.

Authors:  Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2009-10-13       Impact factor: 8.322

6.  Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6.

Authors:  I Tsilioni; A Taliou; K Francis; T C Theoharides
Journal:  Transl Psychiatry       Date:  2015-09-29       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.